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Objective: To study the efficacy and safety of high-concentration antibiotic locks in association with systemic anti- 
biotherapy in Staphylococcus epiderrnidis infections of totally implantable venous access devices (TIVADs) in patients 
with AIDS. 
Methods: Thirty-one episodes of S. epiderrnidis TIVAD infection were observed in nine patients. Locks consisted of 
high concentrations of aminoglycosides or vancomycin according to antibiogram results (susceptibility results obtained 
with the disk diffusion technique). Genotyping of bacterial strains was performed by pulsed-field gel electrophoresis 
(PFGE) in 26 of the 31 infectious episodes. 
Results: The infections occurred within a median period of 62 catheter-days. The median duration of systemic antibiotic 
therapy was 17.5 days in association with a median of three antibiotic locks. Failure as defined by the occurrence of a 
novel episode within 2 months was observed in 17 of the 31 infections (58%). According to the PFGE results, relapse 
with the same strain of S. epiderrnidis or reinfection with a different strain of S. epiderrnidis could be assigned to 10 
episodes which failed to respond to therapy. Relapse was observed in six of 10 episodes. Four episodes were followed 
by the occurrence of a novel infection with a different S. epiderrnidis strain. In one patient, a relapse occurred despite 
TIVAD removal. 
Conclusion: Our observations further document the poor efficacy of associating antibiotic locks with systemic 
antibiotic therapy for the treatment of TIVAD infections in patients with AIDS. 
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INTRODUCTION 
Totally implantable venous access devices (TIVADs), or 
indwelling lines, are commonly used for the manage- 
ment of patients with advanced HIV disease, mostly 
in the context of the treatment of cytomegalovirus 
(CMV) infections. Infection rates associated with the 
use of central intravenous lines have been reported as 
being 0.20 infections per 100 days of catheter use in 
patients with AIDS and 0.041 per 100 catheter-days in 
HIV-seronegative patients [l-61. Several factors con- 
tribute to the increased risk of infection of central 
catheters in patients with AIDS, including irnmuno- 
deficiency, neutropenia, whether it is drug-induced or 
secondary to HIV-related myelotoxicity, and acquired 
impairment of phagocytic function [7,8]. In addition, 
central lines are used daily in patients with AIDS as 
opposed to less frequent use in patients receiving 
chemotherapy for cancer. Staphylococcus epidermidis 
appears to be the leading pathogen of TIVAD-related 
sepsis in patients with AIDS [9]. 
We report on a high rate of relapse or reinfection 
in patients with AIDS with S. epidermidis infections of 
TIVADs, despite the combined use of an antibiotic lock 
and adequate systemic antibiotic therapy. However, 
with the use of molecular typing, reinfection with 
distinct S. epidermidis strains was identified in four of 10 
episodes of failure. Our observations emphasize the 
high morbidity associated with the use of TIVAD in 
patients with advanced HIV disease. 
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PATIENTS AND METHODS 
Nine patients with AIDS were included in an open 
prospective study of the efficacy and safety of a 
combination of an antibiotic lock and systemic anti- 
biotic therapy for the treatment of S. epiderrnidis 
infections of TIVADs. Ten TIVADs were inserted. 
The patient population comprised eight men and 
one woman aged between 32 and 61 years (mean 
age 42 f 7 years) in whom AIDS had previously been 
diagnosed. The past history of opportunistic infections 
at the time of insertion of TIVADs was as follows: 
CMV retinitis in al l  patients, disseminated Mycobacterium 
ai~ium-intr~cellulare in three patients, non-Hodgkin’s 
lymphoma in two patients, cerebral toxoplasmosis in 
one patient, Mycobacteriurn tuberculosis infection in two 
patients, and Kaposi’s sarcoma in one patient. A TIVAD 
was inserted in all patients for intravenous maintenance 
treatment of CMV infection. 
The treatment consisted of the daily administration 
of ganciclovir (5  mg/kg) in eight patients and foscarnet 
(90 mg/kg) in one patient. A TIVAD consisting of a 
central titanium steel chamber connected to a silicone 
rubber outlet catheter (Celsite, Braun-Celsa Labora- 
tories, Chassenteuil, France) was implanted in all 
patients by the same surgical unit. The injection 
reservoir was inserted subcutaneously and fixed to 
the underlying muscle fascia. The outlet catheter 
led into a central vein through a subcutaneous tunnel. 
The catheter tip was positioned in the superior 
vena cava. All patients were taking trimethoprim- 
sulfamethoxazole as prophylaxis for Pneurnocystis carinii 
pneumonitis. Three of the nine patients received anti- 
retroviral therapy with nucleoside analogs. The mean 
CD4+ cell count in the patient group was (17f11) 
x 10b/L (mean f SD) (ranging between 7 and 50). 
The patients entered the study at the time of the 
first TIVAD-related episode of sepsis defined as follows: 
septic syndrome associated with at least two positive 
blood cultures, one drawn from the device and one 
from a peripheral vein. The septic syndrome was 
defined as any of the following: temperature higher 
than 38OC, chills, systemic hypotension, or septic 
shock. Patients who presented with inflammation at the 
puncture site with erythema, tenderness and induration 
with or without purulent discharge were excluded 
from the study as they underwent immediate removal 
of the intravenous device. 
The first antibiotic lock consisted of 60 m g / d  of 
amikacin in 5 mL of heparinized saline (to suit the 
internal volume of the TIVAD) at the time of diagnosis. 
Antibiotic locks were repeated every second day until 
TIVAD blood cultures gave negative results and con- 
sisted of aminoglycosides or vancomycin (40 mg/mL), 
based on the results of the antibiogram. The antibiotic 
solution was considered to remain undisturbed in the 
device for 2 days, as no infusion was allowed in the 
TIVAD. Systemic intravenous antibiotic therapy was 
started as vancomycin (1 g twice daily) on the day of 
diagnosis and then modified according to the results of 
the antibiogram. Blood cultures were performed every 
second day during the first week and once a week 
thereafter for 4 weeks. 
Blood cultures were performed using the Hemo- 
line performance diphasic broth (BioMkrieux, Marcy 
L’Etoile, France) and the Anaer hemocult broth (Sanofi 
Diagnostics Pasteur, Marne-La-Coquette, France), in 
addition to the lysis-centrifugation Isolator system. 
For the purpose of the analysis, we have arbitrarily 
defined success of therapy as the absence of positive 
blood cultures for a period of 2 calendar months from 
the initiation of antibiotic treatment. Failure of therapy 
was defined as ‘immediate’ if blood cultures were 
positive within 15 days of initiation of antibiotic 
treatment, and ‘delayed’ if further positive blood 
cultures occurred between 15 days and 2 months after 
treatment. In the latter case, pulsed-field gel electro- 
phoresis (PFGE) was performed in order to discriminate 
between treatment failure and reinfection. 
PFGE analysis of SrnaI-digested chromosomal DNA 
was performed according to George and Kloos [lo]. In 
brief, DNA was digested overnight with SmaI (New 
England Biolabs Inc., Beverly, Mass, USA) at 30°C. 
DNA fragments were then separated in a 1.2% agarose 
gel. Electrophoresis was performed in ~ 0 . 5  Tris- 
borate-EDTA buffer with a ramped pulse time of 5-30 
s at 6 V/cm for 20 h at 14°C. The gel was stained with 
ethidium bromide (2 mg/L) for 20 min, and visualized 
under UV light. DNA specimens for isolates of the 
same patient were electrophoresed on the same gel 
whenever possible. A molecular size marker (hDNA 
ladder (New England Biolabs Inc., Beverly, MA, USA)) 
was added to each gel for the comparison and 
measurement of DNA bands. As previously described 
[Il l ,  isolates were considered to represent the same 
strain if their DNA profiles differed by 0-7 bands, 
whereas isolates were categorized as unrelated strains 
when their DNA profiles differed by more than seven 
bands. 
RESULTS 
Thirty-one episodes of infection occurred in the nine 
patients during the study period. All the patients 
presented a septic syndrome with temperature higher 
than 38OC associated with at least two positive blood 
cultures, one drawn from the device, and one from a 
peripheral vein. The total number of catheter-days was 
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3748. The mean time between implantation and the 
first TIVAD infection was 155.8 days, with a median 
of 83.0 days (ranging between 17 and 434) (Table 1). 
The mean time to the second infective episode after a 
first episode of TIVAD infection was 79.4 days, with 
a median of 52.5 days (7-303). When all infective 
episodes were considered together in this way, the mean 
was 101.6 catheter-days and the median 62.0 days. All 
patients died during the study period, but none of the 
deaths was directly related to TIVAD infection. No 
death occurred within 2 months following the last 
episode of TIVAD infection. 
The patients were treated for a median time of 17.5 
days (5-29) of systemic antibiotic therapy in association 
with a median of three (1-5) antibiotic locks. The 
median time until TIVAD reuse was 12.5 days (4-24). 
The TIVAD was removed in one patient after two 
antibiotic locks because of persisting fever. Thirteen 
of the 31 infectious episodes recorded (42%) were 
successfully treated, as defined by the absence of 
recurrence within 2 months following the initial 
treatment. In the remaining 58%, another TIVAD 
infection was diagnosed within 2 months. In all these 
cases, no distinction of the S. epidermidis strains was 
possible from the antibiogram. 
Molecular typing was performed on 27 isolates of 
Table 1 Characteristics of the 31 episodes of TIVAD infection 
Interval since 
previous episode of Result of treatment 
Sex/age Episode of TIVAD infection PFGE strains Results assessed assessed by delay of 
Patients (years) TIVAD infection (days) (assigned no.) by PFGE positive blood culture” 
1 M/35 
2 M/32 
3 M/47 
4 M/33 
5 F/40 
6 M/38 
7 M/40 
8 M/47 
9 M/61 
a 
b 
d 
a 
b 
C 
C 
a 
b 
C 
a 
b 
d 
a 
b 
a 
b 
d 
e 
a 
b 
d 
a 
b 
d 
a 
b 
C 
C 
C 
C 
67 
83 
117 
22 
335b 
57 
27 
160b 
13 
105 
44 
7 
38 
13 
199b 
57 
1 7b 
37 
48 
40 
62 
83b 
138 
19 
134 
63b 
294 
203 
23 
434b 
210 
1 
2 
3 
4 
5 
6 
6 
7,8 
9 
7 
ND 
10 
10 
11 
12 
13 
14 
ND 
14 
14 
14 
15 
N D  
ND 
15 
N D  
16 
16 
16 
17 
18 
First infection 
Reinfection 
Reinfection 
Reinfection 
First infection 
Reinfection 
Relapse 
First infection 
Reinfection 
Reinfection 
Infection 
Relapse 
Reinfection 
First infection 
Reinfection 
First infection 
Relapse 
Relapse 
Relapse 
First infection 
Relapse 
Infection 
Relapse 
Relapse 
First infection 
Reinfection 
Success 
Success 
Failure 
Success 
Failure 
Failure 
TIVAD removed 
Failure 
Success 
Success 
Failure 
Failure 
Failure 
TIVAD removed 
Failure 
Success 
Failure 
Failure 
Failure 
Failure 
Success 
Success 
Failure 
Success 
Success 
Success 
Success 
Failure 
TIVAD removed 
Success 
TIVAD removed 
’Success was defined as the absence of positive blood culture for Staphylococtur epidermidis for 2 months. 
bInterval between insertion of TIVAD and first infection episode. 
ND, not determined. 
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S. epidermidis from 26 infectious episodes. This revealed 
18 distinct profiles containing 11-15 bands. All isolates 
with the same profile were from the same patient, and 
there was no association between particular profiles and 
success or failure of therapy (Table 1). In one infection 
episode, two unrelated strains were isolated from each 
of a pair of blood samples, suggesting double infection. 
According to the PFGE results, relapse occurred in 
eight cases and reinfection in nine cases among the 17 
episodes where discrimination was possible. O f  these 
17, 10 occurred in cases of treatment ‘failure’ and seven 
in cases of ‘successful’ treatment (as defined by the 
absence of further positive blood cultures for a period 
of 2 months from the treatment of the previous 
episode). The 10 episodes in failures of treatment 
comprised six relapses and four reinfections, while the 
seven cases after successful treatment of the previous 
episodes comprised two relapses and five reinfections. 
An example of relapse is seen in lanes 4 and 5 of Figure 
1. There was no relationship between the time of 
occurrence of a new episode of infection within the 2- 
month observation period either with the S. epidermidis 
4485 
448.5 
1 2 3 4 5 6  
Figure 1 Analysis of total DNA of S. epidevrnidis by 
pulsed-field agarose gel electrophoresis in patients who 
failed to respond to therapy with the occurrence of early 
relapses of TIVAD infection. Total DNA was digested with 
SrnaI. Lanes 1, 2 and 3: three strains with distinct PFGE 
profiles isolated from three infectious episodes in the same 
patient. Lanes 4 and 5: two strains with identical PFGE 
profiles isolated from two infectious episodes in the same 
patient. Lane 6: lambda ladders used as size markers. 
Fragment sizes are indicated on the right (kb). 
genotype or with relapse of infection, as opposed to 
novel infection. In one particular patient, an additional 
infection with the same S. epidermidis strain was 
observed 38 days after initiation of antibiotic therapy, 
despite the removal of the TIVAD, indicating that the 
relapse in any patient may proceed from the persistence 
of colonization of the skin with the causative bacterial 
strain. 
DISCUSSION 
In the last several years, TIVADs have been commonly 
used in the management of AIDS patients with long- 
term maintenance antiviral therapy for CMV infection, 
parenteral nutrition, and administration of chemo- 
therapy and blood products. Sepsis is a serious and 
frequent complication of TIVADs. We report on 32 
episodes of infection with S. epidermidis. Previously 
published studies in AIDS have documented S. 
epidermidis infection as accounting for 25-60%, of the 
cases [6,12], in addition to S. uureus in 47-870/0 [2,13]. 
The decision not to systematically remove the 
infected line may improve the patients’ quality of life. 
In this respect, it is of interest that antibiotic locks have 
been shown to be effective either alone or in com- 
bination with systemic antibiotics in HIV-negative 
patients with indwelling catheter-related sepsis [ 14-1 61. 
However, there are few data on the results of antibiotic 
locks in HIV-infected patients with TIVAD-related 
sepsis, and the efficacy of this approach is considered to 
be poor. Thus, a study of 15 catheter-related sepsis 
episodes in 12 HIV-infected patients treated by local 
and systemic antibiotics has shown a success rate of 
16% [17]. It has been suggested that the lack of efficacy 
of antibiotic locks may be related to persistence of 
organisms in clots under the TIVAD septum [18]. In 
the present study, anticoagulation of TIVADs with 
locally administered heparin was systematically per- 
formed every day. 
The overall rate of failure that we observed was 
58%. However, PFGE was useful to distinguish between 
relapse with similar strains of S. epidermidis and re- 
infection with genotypically different strains of S. 
epidermidis. Nevertheless, the proportion of relapse 
observed in the study could be overestimated, as 
reinfection by a strain harbored on the patient skin with 
a PFGE-identical strain may be possible. A relapse with 
the same S. epidermidis strain was observed in one 
patient, despite the removal of the TIVAD, indicating 
that the relapse may proceed from the persistence of 
colonization of the skin with the causative bacterial 
strain. 
Our results confirm the limitations of using anti- 
biotic locks in association with systemic antibiotic 
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therapy for the treatment of S. epidermidis TIVAD 
infection in patients with AIDS. 
References 
1. Skoutelis AT, Murphy RL, MacDonell KB, et al. Indwelling 
central venous catheter infections in patients with the acquired 
immune deficiency syndrome. J Acquir Immune Defic Syndr 
2. Van der Pijl H, Frissen PH. Experience with totally implantable 
venous access device (Port-A-Cath) in patients with AIDS. AIDS 
3. Prichard JG, Nelson MJ, Burns L, Kaplowitz HJ, Caillovet BL, 
Sanchez MA. Infections caused by central venous catheter in 
patients with acquired immunodeficiency syndrome. South Med 
4. Stanley HD, Charlebois E, Harb G, Jacobson MA. Central 
venous catheter infections in AIDS patients receiving treatment 
for cytomegalovirus disease. J Acquir Immune Defic Syndr 1994; 
5. Dega H, Eliaszewicz M, Gisselbrecht M, et al. Infections 
associated with totally implantable venous access devices (TIVAD) 
in human immunodeficiency virus-infected patients. J Acquir 
Immune Defic Syndr 1996; 13: 146-54. 
6. Fernadez-Martin J, Salmon-Ceron D, Leport C, et al. Septichie 
sur cathkters veineux centraux implant& chez les malades atteints 
de SIDA. Med Mal Infect 1992; 12: 913-18. 
7. Lane HC, Masur H, Whalen GH, Rook AH, Fauci AS. 
Abnormalities of B-cell function and immunoregulation in 
patients with the acquired immunodeficiency syndrome. Ann 
Intern Med 1986; 104: 511-14. 
8. Murphy PM, Lane HC, Fauci AS, Gallin JI. Impairment of 
neutrophil bactericidal capacity in patients with AIDS. J Infect 
Dis 1988; 158: 627-30. 
9. Piketty C, Gilquin J, Buu-Hoi A, Gutmann L, Kazatchkine MD. 
Efficacy and safety of an antibiotic-lock technique in infected 
implantable venous access devices in patients with AIDS [abstract 
1990; 3: 335-42. 
1992; 6: 709-13. 
J 1988; 81: 1496-8. 
7: 272-8. 
1201. Presented at 2nd National Conference on Human Retro- 
virus and Related Infections, Washington, 1995. 
10. George C, Moos WE. Comparison ofthe SmaI-digested chromo- 
somes of Staphylococcus epidermidis and the closely related species 
Staphylococcus capitis and Staphylococcus caprae. Int J Syst Bacteriol 
1994; 44: 404-9. 
11. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromo- 
somal DNA restriction patterns produced by pulsed-field gel 
electrophoresis: criteria for bacterial strain typing. J Clin Micro- 
biol 1995; 33: 2233-9. 
12. Henri K, Thurn JR,  Johnson S. Experience with central venous 
catheter in patients with AIDS. N Engl J Med 1989; 320: 1496. 
13. Ravighone MC, Battan R ,  Pablos-Mendez A, Aceves-Casillas P, 
Mullen MP, Taranta A. Infections associated with Hickman 
catheters in patients with acquired immunodeficiency syndrome. 
Am J Med 1989; 86: 780-6. 
14. Messing B, Peitra-Cohen S, Debure A, et al. Antibiotic-lock- 
technique: a new approach to optimal therapy for catheter- 
related sepsis in home-parented nutrition patients. J Parenteral 
Enteral Nutrition 1988; 12: 185-9. 
15. Flynn PM, Shenep JL, Stokes DC, et al. In situ management of 
confirmed central venous catheter-related bacteriemia. Pediatr 
Infect Dis J 1987; 6: 729-34. 
16. Douard MC, Arlet G, Leverger G, et al. Quantitative blood 
cultures for diagnosis and management of catheter-related sepsis 
in pediatric hematology and oncology patients. Intensive Care 
Med 1991; 17: 30-5. 
17. Geofiay C, Khuong MA, Coulaud JP. Long term evaluation of 
antibiotic-lock technique in totally implantable venous access 
device (TIVAD) in patients with AIDS [abstract 16791. Presented 
at 33rd Interscience Conference on Antimicrobial Agents and 
Chemotherapy, New Orleans, 1993. 
18. Longuet P, Douard MC, Maslo C, et d. Limited efficacy of 
antibiotic lock technique in catheter related bacteriemia of 
totally implanted ports in HIV infected and oncologic patients 
[abstract 51. Presented at 35th Interscience Conference on 
Antimicrobial Agents and Chemotherapy, San Francisco, 1995. 
